NCCN publishes guidelines for pediatric Ewing sarcoma
NCCN publishes guidelines for pediatric Ewing sarcoma The Cancer Letter
NCCN publishes guidelines for pediatric Ewing sarcoma The Cancer Letter
FDA Approves Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer Oncology News Central
FDA одобрило атезолизумаб при раке ободочной кишки III стадии UA.NEWS
MAMMÔ 2026 Day 1 Highlights: From Early Detection and Precision Diagnostics to Treatment De-escalation and Global Breast Cancer Care Oncodaily
FDA approves atezolizumab combination for stage III colon cancer with deficient DNA mismatch repair News-Medical
Real-World Evidence in Cancer Care: Research and Treatment Decisions – ESMO Oncodaily
Edna Cukierman: Strengthening Connections Across the Cancer Research Community Oncodaily
National PA Week: PA-Nurse Synergy Transforms Outpatient Hematology Care Oncology Nursing News
Eric Lefkofsky: The Evolving Role of Sequencing in Individualized Cancer Care Oncodaily
Ashley Marton, M.D.C.M., Joins The Eugene M. and Christine E. Lynn Cancer Institute as a Hematologist and Medical Oncologist Florida Hospital News and Healthcare Report
Asem Mansour: Shisha Revenues Cannot Offset the Cost of Cancer Treatment Oncodaily
Wafik El-Deiry: Exploring N-of-1 Precision Oncology With Razelle Kurzrock Oncodaily
The FDA has approved atezolizumab plus chemotherapy as an adjuvant treatment for patients aged 2 years and older with stage III mismatch repair deficient colon cancer. Atezolizumab (Tecentriq, Genentech) in combination with a fluoropyrimidine and oxaliplatin is now the first adjuvant immunotherapy regimen approved for…
Karen Knudsen: Expanding Access to Clinical Trials as a Critical Part of Cancer Care Oncodaily